Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01003678
First received: October 27, 2009
Last updated: May 8, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)